Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.50 |
| ▸ | F2R | P25116 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771456 | 1.00 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL3766322 | 0.88 | KCNK3 (0.56) | KCNK3KCNK9 | |
| SCHEMBL3776657 | 0.88 | KCNK3 (0.56) | KCNK3KCNK9 | |
| SCHEMBL3768793 | 0.87 | PTGES (0.66) | MEN1KMT2ASMN1; SMN2KCNK3KCNK9 | |
| SCHEMBL3777535 | 0.87 | PTGES (0.52) | MEN1KMT2AKCNK3KCNK9PTGES | |
| SCHEMBL3770507 | 0.87 | PTGES (0.66) | MEN1KMT2ASMN1; SMN2KCNK3KCNK9 | |
| SCHEMBL3770521 | 0.87 | F2R (0.55) | MEN1KMT2ANPC1RAB9AKCNK3 | |
| SCHEMBL3764346 | 0.87 | PTGES (0.52) | MEN1KMT2AKCNK3KCNK9PTGES | |
| SCHEMBL3777602 | 0.87 | F2R (0.55) | MEN1KMT2ANPC1RAB9AKCNK3 | |
| SCHEMBL3772371 | 0.87 | KCNK3 (0.58) | KCNK3KCNK9F2RPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | MEN1 668/4885KMT2A 4126/4885SMN1; SMN2 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.